PRESS RELEASE
News
-
-
-
REGULATED PRESS RELEASE
NFL Biosciences presents the immunological analysis results of its phase 2 CESTO II study confirming the efficacy of NFL-101, its first-in-class treatment for tobacco addiction
NFL Biosciences presents immunological analysis results of phase 2 CESTO II study confirming efficacy of NFL-101 for tobacco addiction. Association between anti-tobacco IgG increase and continuous abstinence strengthens evidence -
-
-
PRESS RELEASE
Publication of Offering Circular relating to the issuance of inaugural Additional Tier 1 securities
Metro Bank Holdings PLC has priced its inaugural £250m 13.875% fixed rate reset perpetual subordinated contingent convertible capital securities to optimize capital structure and support growth -
-
PRESS RELEASE
EQS-Adhoc: Vectron Systems AG: Agreement on Severance and Compensation Payment between Vectron and Shift4 Group under the domination and profit and loss transfer agreement
Vectron Systems AG and Shift4 Group agree on severance and compensation payment under domination and profit transfer agreement, with fixed annual compensation payment set at EUR 0.47 per share -
-
PRESS RELEASE
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference
